
    
      This open label, multicenter phase I study is designed to evaluate the safety, tolerability,
      pharmacokinetics and preliminary efficacy in advanced solid tumors or lymphoma treated with
      anti- PD-1 monoclonal antibody SCT-I10A. The trial will be divided into two parts:
      dose-exploration and indication expansion.
    
  